MX2023007162A - Macrociclos y sus usos. - Google Patents

Macrociclos y sus usos.

Info

Publication number
MX2023007162A
MX2023007162A MX2023007162A MX2023007162A MX2023007162A MX 2023007162 A MX2023007162 A MX 2023007162A MX 2023007162 A MX2023007162 A MX 2023007162A MX 2023007162 A MX2023007162 A MX 2023007162A MX 2023007162 A MX2023007162 A MX 2023007162A
Authority
MX
Mexico
Prior art keywords
macrocyclic compounds
macrocycles
cancer
present disclosure
methods
Prior art date
Application number
MX2023007162A
Other languages
English (en)
Spanish (es)
Inventor
Evan W Rogers
Jingrong J Cui
Eugene Rui
Original Assignee
Blossomhill Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blossomhill Therapeutics Inc filed Critical Blossomhill Therapeutics Inc
Publication of MX2023007162A publication Critical patent/MX2023007162A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
MX2023007162A 2020-12-17 2021-12-16 Macrociclos y sus usos. MX2023007162A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063126722P 2020-12-17 2020-12-17
US202163279850P 2021-11-16 2021-11-16
US202163284789P 2021-12-01 2021-12-01
US202163289014P 2021-12-13 2021-12-13
PCT/US2021/063721 WO2022133037A1 (en) 2020-12-17 2021-12-16 Macrocycles and their use

Publications (1)

Publication Number Publication Date
MX2023007162A true MX2023007162A (es) 2023-06-29

Family

ID=82058646

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007162A MX2023007162A (es) 2020-12-17 2021-12-16 Macrociclos y sus usos.

Country Status (12)

Country Link
US (1) US20240182487A1 (cg-RX-API-DMAC7.html)
EP (1) EP4262796A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023553835A (cg-RX-API-DMAC7.html)
KR (1) KR20230121773A (cg-RX-API-DMAC7.html)
AU (1) AU2021401741A1 (cg-RX-API-DMAC7.html)
CA (1) CA3202770A1 (cg-RX-API-DMAC7.html)
IL (1) IL303419A (cg-RX-API-DMAC7.html)
MX (1) MX2023007162A (cg-RX-API-DMAC7.html)
PY (1) PY21110949A (cg-RX-API-DMAC7.html)
TW (1) TWI923651B (cg-RX-API-DMAC7.html)
UY (1) UY39574A (cg-RX-API-DMAC7.html)
WO (1) WO2022133037A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250022117A (ko) * 2022-06-08 2025-02-14 블로썸힐 테라퓨틱스, 인크. 인다졸 거대고리 화합물 및 그의 용도
AU2023282906A1 (en) * 2022-06-08 2024-11-28 Blossomhill Therapeutics, Inc. Indazole containing macrocycles and their use
CN119013283A (zh) * 2022-07-27 2024-11-22 上海和誉生物医药科技有限公司 大环egfr抑制剂及其制备方法和药学上的应用
JP2026507655A (ja) * 2023-02-22 2026-03-04 ユーハン・コーポレイション Egfr阻害剤としての大環状アミノピリジン化合物
JP2026507653A (ja) * 2023-02-22 2026-03-04 ユーハン・コーポレイション Egfr阻害剤としての大環状アミノピリジン化合物
CN120981466A (zh) * 2023-02-22 2025-11-18 柳韩洋行 作为egfr抑制剂的大环氨基吡啶化合物
WO2024209363A1 (en) 2023-04-06 2024-10-10 Pfizer Inc. Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators
JP2026517554A (ja) * 2023-05-02 2026-06-02 ブロッサムヒル・セラピューティクス・インコーポレイテッド 疾患の処置のためのegfr阻害剤
JP2026521264A (ja) * 2023-06-23 2026-06-29 ブロッサムヒル・セラピューティクス・インコーポレイテッド 大環状インダゾール化合物の併用療法
TW202527935A (zh) * 2023-12-07 2025-07-16 美商榮山醫藥股份有限公司 吲唑巨環多晶型物
IL328856A (en) * 2023-12-08 2026-08-01 Blossomhill Therapeutics Inc Indazole-based macrocyclic compounds
WO2025199438A1 (en) * 2024-03-22 2025-09-25 Blossomhill Therapeutics, Inc. 7-azaindazole macrocycles and their use
WO2025245175A1 (en) * 2024-05-22 2025-11-27 Ajax Therapeutics, Inc. Macrocyclic heteroaromatic inhibitors of jak2
WO2026064346A1 (en) * 2024-09-18 2026-03-26 Blossomhill Therapeutics, Inc. Tetracyclic-macrocycles and their use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3062B1 (ar) * 2010-10-05 2017-03-15 Lilly Co Eli R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
CA2863892C (en) * 2012-03-06 2016-08-30 Pfizer Inc. Macrocyclic derivatives for the treatment of proliferative diseases
EP3333157B1 (en) * 2015-08-07 2020-12-23 Harbin Zhenbao Pharmaceutical Co., Ltd. Vinyl compounds as fgfr and vegfr inhibitors
CN111269245B (zh) * 2018-12-04 2021-08-27 杭州百新生物医药科技有限公司 一种环状氨基嘧啶衍生物及其抑制激酶的活性和用途
IL317393A (en) * 2018-12-21 2025-02-01 Revolution Medicines Inc Compounds that participate in covalent bonds and their uses

Also Published As

Publication number Publication date
PY21110949A (es) 2023-08-07
TW202241911A (zh) 2022-11-01
WO2022133037A1 (en) 2022-06-23
EP4262796A1 (en) 2023-10-25
IL303419A (en) 2023-08-01
JP2023553835A (ja) 2023-12-26
TWI923651B (zh) 2026-05-01
EP4262796A4 (en) 2025-04-02
US20240182487A1 (en) 2024-06-06
KR20230121773A (ko) 2023-08-21
CA3202770A1 (en) 2022-06-23
AU2021401741A9 (en) 2024-09-19
AU2021401741A1 (en) 2023-06-29
UY39574A (es) 2022-07-29

Similar Documents

Publication Publication Date Title
PY21110949A (es) Macrociclos y sus usos
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
CL2023000061A1 (es) Macrociclos y su uso
CO2020000633A2 (es) Compuestos macrocíclicos y usos de los mismos
MX2025000271A (es) Inhibidores de kras de anillo fusionado para el tratamiento de enfermedades
UY39779A (es) Compuestos macrocíclicos para tratar enfermedades
ECSP20069418A (es) Compuestos heterocíclicos como inmunomoduladores
UY37272A (es) Piridinas sustituidas con heteroarilo y métodos de uso
MX2018005890A (es) Composiciones para tratar atrofia muscular espinal.
BR112017010188A2 (pt) análogos de éter fosfolipídeos como veículos de fármacos alvejando câncer
UY36702A (es) Piridinas sustituidas y métodos de uso
CR20240533A (es) Macrociclos de indazol y su uso
CO2021008117A2 (es) Compuestos de imidazopiridazina e imidazopiridina como inhibidores de quinasa-2 de tipo receptor de activina
ECSP22044525A (es) Terapia de combinaci?n que comprende un inhibidor de alk2 y un inhibidor de jak2
CO2022008817A2 (es) Macrociclos para uso en el tratamiento de enfermedades
MX2024014995A (es) Macrociclos que contienen indazol y su uso
CO2022014837A2 (es) Células t v delta1+ para el tratamiento de neoplasias mieloides
MX2024007929A (es) Tetrahidropirazolopirimidinas y analogos relacionados para la inhibicion de yap/taz-tead.
CO2025016647A2 (es) Inhibidores de egfr para el tratamiento de enfermedades
GT200700020A (es) Compuestos y derivados de dibencilamina
MX2022010945A (es) Usos terapeuticos de compuestos macrociclicos.
ECSP22093652A (es) Compuestos de imidazopiridazina y usos de los mismos
DOP2025000274A (es) Inhibidores de egfr para el tratamiento de enfermedades
CL2022002527A1 (es) Células t v delta1 para el tratamiento de neoplasias mieloides
BR112017023121A2 (pt) composto, composição farmacêutica, processo para a preparação de uma composição, método de tratamento do câncer, kit para o tratamento terapêutico do câncer e uso de um composto